A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed MF, Chen L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 2018, 175: 313-326. PMID: 30290139, PMCID: PMC6538253, DOI: 10.1016/j.cell.2018.09.035.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsCancer immunotherapyImmune normalizationFrequent immune-related adverse eventsB7-H1/PDHigher objective response rateFuture cancer immunotherapyObjective response rateRare objective responsesAntitumor immune responseImmune activation mechanismsObjective responseAdverse eventsImmune enhancementTumor responseImmune deficiencyCancer indicationsDifferent therapiesImmune responseToxicity profileImmunotherapyResponse rateFDA approvalTumor microenvironmentDistinct mechanisms